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8SUMMARY
A large number of human DNA sequence variations have been identified and categorized
as pathogenic or non-pathogenic based on their influence to the phenotype. Both types of
variations have been collated into registries that are typically distributed through the Internet.
The primary immunodeficiencies (PIDs) form a distinct group of mainly rare syndromes.
More than 2700 patients have been diagnosed and the mutation and patient data collected
into locus-specific databases. This study has concentrated on increasing the quality of the
PID information on several levels.
Using a novel database format developed during the study, a number of locus-specific
mutation databases were constructed and maintained. The data in the registries was used
to analyse the underlying mutation mechanisms, especially deamination of methylated
cytosines. As primary sequence of the affected proteins cannot be used to predict the
putative changes in the biophysical properties of mutated structures, a bioinformatical
method was developed for mutational analyses. The method applies structural homology
when experimental three-dimensional structure of the defective protein is not available. By
using structure-derived rules, the structure-function consequences of missense mutations
in two distinct protein module families, Src homology 2 (SH2) and DNA methyltransferase
domains, were analysed. In addition, pathogenic mutations were introduced into the SH2
domain of Bruton tyrosine kinase and analysed by using various biochemical methods.
The experimental results verified the bioinformatical predictions for the pathogenic mutations
in Bruton tyrosine kinase.
9INTRODUCTION
The human genome sequence has been revealed and an enormous amount of variations
mapped onto it. Majority of the DNA sequence variations results from short insertions,
deletions or changes of single nucleotides. The variations can be categorized as pathogenic
and non-pathogenic based on their influence to the phenotype. Today, more than 1500
different genes have been linked to a disease.
Primary immunodeficiencies (PIDs) are a group of mainly rare syndromes affecting various
parts of the immune system. Although the symptoms of several PIDs are similar, more
than hundred distinct phenotypes have been characterized. After diagnosis of the disease,
a proper treatment is available for many of the PIDs and the patients may live fairly normal
life. IMT Bioinformatics maintains and develops a knowledge base for PIDs including more
than 80 different locus-specific mutation databases with roughly 2700 patients. The
knowledgebase also provides curated disease information for the scientists, physicians
and patients and software for mutation analyses and data distribution. The present study
has concentrated on increasing the quality of the PID information on several levels.
A number of locus-specific mutation databases were created to store the mutation and
patient information. In the first phase, a novel database format was developed for the
BTKbase following the guidelines published by Human Genome Variation Initiative. The
format was then applied to other constructed locus-specific mutation databases. In addition,
a generic registry for Src homology 2 (SH2) domain mutations was created. The registry
provides tools for accessing mutation and patient data from the individual locus-specific
mutation databases and allows further studies, such as genotype-phenotype correlations.
Secondly, the data in the registries was used to analyse the effect of the neighbouring
nucleotides for the mutation process, especially in deamination of methylcytosine into
thymine.
Currently, all the PID related locus-specific mutation registries describe the effects of a
particular mutation to the mRNA and protein levels directly from the analyses of genomic
DNA. Although the biophysical properties of proteins are determined by the amino acid
sequence, it is not possible to predict the biophysical properties of the mutated protein
structure directly from its primary sequence. Therefore, the third aim of this study was to
develop a bioinformatical method that could be applied to a range of protein domains
comprising thousands of PID causing mutations. The approach exploits structural homology
among the family members when structural information is not available. Comparative
modelling was used to build the defective protein domain structure based on a homological
experimentally solved structure, and the structural consequences of the pathogenic
mutations were analysed based on set of structure-derived rules and sequence entropy,
e.g. the introduced side chain χ-angles were rotated to study if it can adopt a known rotamer
on the corresponding structure.
The method was applied to two diverse protein domains, the Src homology 2 (SH2) and
DNA methyltransferase domains, to study the structure-function consequences of eighty-
nine different pathogenic amino acid substitutions. SH2 domains are a well-characterized
protein module family that recognize phosphorylated tyrosines almost invariably in specific
sequence contexts. These domains have been shown to mediate protein-protein interactions
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in many signal transduction pathways or intramolecular contacts that regulate enzyme
activity. Pathogenic mutations affecting seven different SH2 domains have been identified
from nine disease phenotypes. The methyltransferase domains catalyse the transfer of a
methyl group from S-adenosyl-L-methione to the target cytosine in DNA. The effects of
DNA methylation are widespread including e.g. transcriptional repression by methylation of
promoter regions and X-chromosome inactivation. Mutations in the gene encoding for a
DNMT3B, lead to an autosomal recessive Immunodeficiency, Centromeric instability and
Facial anomalies (ICF).
To validate the method, six disease-causing mutations were cloned into the SH2 domain of
Bruton tyrosine kinase (BTK). The mutated proteins were analysed for their consequences
to the protein structure and function by using circular dichroism (CD) spectroscopy, and for
their ability to bind to phosphotyrosine. Three of the mutants were also introduced into full-
length BTK protein and transiently expressed in COS-7 cells to analyse the differences in
stability between isolated SH2 domain mutants and BTK in vivo. The biochemical analyses
verified the bioinformatical predictions of the mutation consequences on BTK SH2 domain
structure model.
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REVIEW OF THE LITERATURE
1 The Human Genome
The sequencing of the human genome was completed April 2003. As we learn more about
human biology, additional layers of information will be mapped to the genome. One such
layer consists of all types of DNA variations identified during the Human Genome Project
(HGP) and by various groups studying polymorphisms and human diseases. The mapping
of the genome has not only accelerated the cloning of disease-associated genes but also
increased our understanding of how disease-causing variations differ from normal
polymorphisms. The detailed discussion of genome composition appeared in the published
draft sequences (McPherson et al., 2001; Venter et al., 2001).
1.1 DNA Structure
The genetic information is stored in the structure of the deoxyribonucleic acid (DNA). In
1953, Watson and Crick described how two complementary DNA chains could coil around
each other to form the helical structure (Watson and Crick, 1953). In their structure, the
nucleotides are inside of the helix, perpendicular to the common axis. The adenine (A) and
guanine (G) are aromatic heterocyclic purines, whereas the cytosine (C) and thymine (T)
consist of a single aromatic ring and are pyrimidines. As a result, the nucleotides can only
fit inside the helix, if a purine bonds with a pyrimidine from the opposite DNA chains. Specific
hydrogen bonds between G and C as well as between T and A generate complementary
base pairing. The backbone is formed of phosphodiester bonds between the deoxyribose
groups. The negative phosphate groups remain on the outside the helical structure and are
available to interact with surrounding molecules. The two DNA chains run in opposite
directions.
1.2 Genomic organization
The human genome consists of approximately three billion DNA base pairs organized into
23 chromosome pairs. 22 of these are autosomes and the remaining pair is formed by the
sex chromosomes. The composition reflects both functional and structural elements of the
genome (Figure 1A).
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Figure 1 A - Although the 30000-35000 human genes comprise a quarter of our genome, only 1.5% of the DNA
encodes for proteins. Majority of the genome consists of different type of repeating sequences. The figure was
modified from the original one appearing in (Dennis and Gallagher, 2001). The data was published in (McPherson
et al., 2001) B - The SNPs affecting phenotype are either located in the regulatory or coding regions. Variants
affecting splice sites are included either in exon or intron categories.
1.2.1 Repeating sequences
More than half of the nucleotides in our genome form repetitive sequences, with the vast
majority of these accounted for by repeats derived from parasitic DNA sequences, known
as transposons. Long interspersed sequences (LINEs) are the most ancient repeating unit
in human genome. These transposons are roughly 6000 bp of length encoding the machinery
for copying itself, whereas the short interspersed elements (SINEs, roughly 100-400 bp)
implement the LINEs machinery for transposition. The most abundant repeating unit with a
million copies in the genome is the Alu element belonging to the latter group of transposons.
The observation of Alus near genes in GC and AT rich regions may be explained by a their
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role in protein translation regulation under conditions of stress. Dispersed Alu segments
also exhibit significant differences in tissue-specific cytosine methylation levels (reviewed
in Schmid, 1998). Of the transposons, only LINE1 and Alu are still active in our genome.
Roughly 3% of the human genome consists of repeats of just a few bases and 5% of
duplications of larger segments. With the exception of Alus, repetitive DNA is enriched in
AT rich regions. These areas are thought to be involved in the structure and reshaping of
the chromosome by rearranging it to create new genes or modify the existing ones. The
repeating sequences enclose a large number of DNA variations.
1.2.2 Unique sequences
A gene consists of a specific sequence of bases containing information to build protein(s).
Genes are further split into exons and introns, the former encoding for proteins. Interestingly,
only 1.5% of our genome encodes for proteins. The 30-35000 genes are unevenly distributed
among the genome forming large gene-rich segments.
Normal males have X and Y-chromosomes, whereas females have two copies of the X
chromosome. Hence, genes located outside sex chromosomes are available as two alleles
situated in a locus that describes the chromosomal location of the gene.  Typically genes
are located in segments with higher C+G content than the genome average of 41%. This is
partly due to a high selection pressure to preserve the nucleotide composition in the coding
regions undamaged. The human promoter regions have also been shown to be associated
with CpG islands, segments of DNA with a very high concentration of CpG dinucleotides
(Bird, 1986; Larsen et al., 1992). These islands are involved in regulation of gene transcription
in the germline and early embryonic cells. The majority of cytosines in CpG dinucleotides
are methylated, whereas cytosines in CpG islands are unmethylated. The promoters without
CpG islands are methylated in sperm and are always associated with tissue-specific genes
(Antequera, 2003). The spontaneous deamination of methylated cytosines to thymine
underlies in many human diseases.
1.2.3 From genes to proteins
The concept of a single gene encoding a particular native protein structure with one in vivo
function is an over-simplification. Proteins may have more than one function. Most proteins
consist of a variety of domains, independently folding modules with an evolutionary
conserved function(s). Interactions between domains can affect the protein structure, stability
and function (e.g. Altroff et al., 2001). As an example, a transient attachment of a small and
highly negative phosphate group has been shown to act as a switch between the inactive
and active enzyme conformations or by locating the molecule to its correct pathway (reviewed
in Hubbard and Till, 2000).
The protein diversity is further increased by utilization of alternative promoters, multiple
transcription start sites, modified polyadenylation or alternative splicing (reviewed in Landry
et al., 2003 and Shabalina and Spiridonov, 2004). The encoded protein isoforms may differ
in function, tissue-specific expression profile, cellular location or involvement in human
diseases (Mironov et al., 1999; Caceres and Kornblihtt, 2002; Roberts and Smith, 2002).
Recently, splice-variants have been shown to either insert or delete complete protein domains
or target functional residues more frequently than expected (Kriventseva et al., 2003).
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Furthermore, high conservation in alternative and constitutive splice sites between the
human and mouse transcripts has been observed (Thanaraj et al., 2003). A large number
of splice-variants, however, introduce a termination codon and the encoded protein product
is likely to be highly unstable. These aberrant transcripts are detected and degraded rapidly
by specific nonsense-mediated mRNA decay machinery (Maquat, 2002).
1.3 Genetic variation
The humans are almost identical to each other in their genomic DNA sequences. On average,
our genomes differ only by 0.1% from each other and we are approximately 98.8% identical
to chimpanzees at the nucleotide level (Clark et al., 2003). The pattern of variation in modern
populations is dependent on our past. Historic population size, structure and genetic drift
influence the pattern of variation across the whole genome. Natural selection, on the other
hand, affects specific regions at particular loci through mutation and recombination.
Variations between individuals form the genetic background responsible for biological and
physical differences, such as colour of hair, susceptibility to a disease and response to
treatment.
New alleles are introduced to gene loci by spontaneous endogenous processes or induced
by various exogenous agents, such as UV radiation or tobacco smoke. Although these
processes are rare, they constantly create new variations in the human population. The
fate of the new mutation depends on its effect on the phenotype. Types of genetic variation
vary in length, frequency and distribution. Chromosomal rearrangements involve
duplications, inversions, translocations or deletions of large genomic segments. Most genetic
variation, however, results from short insertions, deletions or changes of single nucleotides.
1.3.1 Single Nucleotide Polymorphims (SNPs)
By a strict definition, a SNP is a site where two nucleotides have been found in a specific
population with the minor allele present in greater than 1%. An analogous disease-causing
mutation typically has an allele frequency of below 1% with highly penetrating phenotype.
However, the SNP definition is not applied strictly in public variation databases, and the
allele frequency also depends on inheritance pattern.
The probability of a nucleotide position being heterozygous when comparing two
chromosomes chosen randomly from the population is represented by a normalized
heterozygosity (π). Depending of the number of chromosomes and the ratio of analyzed
populations, π is approximately 5⋅10-4 (Cargill et al., 1999; Halushka et al., 1999;
Sachidanandam et al., 2001; Venter et al., 2001). The heterozygosity is relatively constant
among the autosomes, but decreases in sex chromosomes. The lower nucleotide diversity
in the X- and Y-chromosomes may be explained as a combination of smaller effective
population size and strong selection due to hemizygosity in males (Sachidanandam et al.,
2001).
The SNP allele frequency has been shown to correlate with the allele age, population
specificity and functional class (Halushka et al., 1999). The majority of SNPs have a minor
allele frequency of less than 10%. These are relatively new variations found only in specific
populations. Individual genes also differ in their nucleotide diversity (Halushka et al., 1999;
Sachidanandam et al., 2001). As an example, particular non–coding regions in the HLA
15
locus show extremely high sequence variation owing to the balancing selection, whereas
non-coding regions of seven X-linked loci have low nucleotide diversity (Horton et al., 1998).
Generally, SNPs are less abundant in the exons than in the non-coding regions (Cargill et
al., 1999; Halushka et al., 1999; Salisbury et al., 2003). However, these publications focused
on coding regions and surveyed only limited portions of non-coding sequences.
SNPs with minor allele frequency of at least 1% have been shown to occur at a rate of 200-
300 bp through the genome (Kruglyak and Nickerson, 2001; Stephens et al., 2001),
suggesting as many as 15 million common SNPs in the human genome. These SNPs can
be classified based on their genomic location (Figure 1B). The coding SNPs can be further
divided into three categories based on their effect on the protein structure. Synonymous
SNPs have no effect at the protein level as the new codon still encodes for the same
residue. Non-synonymous SNPs may either lead to an amino acid substitution (missense)
or a truncated protein (nonsense). Comprehensive variation studies including a large number
of genes have found approximately four coding SNPs per gene with 40% of them being
non-synonymous (Cargill et al., 1999; Halushka et al., 1999). Hence, the total number of
non-synonymous SNPs is expected to be 48-56 000. These SNPs, together with still an
unknown number of regulatory and other functional non-coding polymorphisms, are
considered to form the pool of potential phenotype altering variations in the human genome.
1.3.2 Databases of normal variation
The SNP consortium, formed by several companies and academic institutions, was
established in 1999 to produce a public resource of human SNPs (Thorisson and Stein,
2003). As the Human Genome was published, the consortium released more than 1.4
million SNPs collected from 24 ethnically diverse individuals (Sachidanandam et al., 2001).
During the past two years, a number of other large-scale analyses of SNPs in specific
populations or genes related to specific diseases have been published (Martin et al., 2000;
Hirakawa et al., 2002; Lee et al., 2003). In addition to public variation databases, companies,
such as Celera Genomics, provide access to their private databases lifting the number of
non-redundant human genetic variations over six million. The publicly available information
is deposited into two public databases, the Human Genome Variation database (HGVbase)
and dbSNP (Wheeler et al., 2003; Fredman et al., 2004). The databases are listed together
with some disease-causing mutation databases in the Table 1.
The non-pathogenic sequence variation databases include several problems caused by
the massive increase of data in a short period of time as well as our inaccurate methods to
model complex human biology. As an example, the precise exon structure on the genome
is still likely to change as new genomes are sequenced and the algorithms detecting exons
are refined to improve accuracy. Furthermore, public databases include a number of
sequencing errors and SNPs located in pseudogenes (Ng and Henikoff, 2002). Some SNPs
may also be associated with complex diseases. The current version of HGVbase (v.15)
contains 2.8 million DNA variants, only 6.5% of the variations have been verified and 1.4%
includes information about allele frequency.
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Table 1. A partial list of human variation societies and databases.
Partly to correct the current situation, the International HapMap Project was initiated in
2002 (Consortium, 2003). The aim of the project is to provide publicly available set of
common patterns of DNA sequence variation from three populations originating from parts
of Africa, Asia and Europe by determining the allele frequencies and the degree of association
between the variations. The resulting haplotype map can be used to e.g. identify association
between a specific variant and a disease indirectly by comparing a group of affected
individuals with a group of unaffected controls (Collins et al., 1997).
2 Genetics in Human Diseases
All types of sequence variations in germline DNA have been shown to cause diverse
phenotypes. Chromosomal rearrangements affect the copy number of genes and disease
results from a gene dosage effect. In contrast, the coding SNPs may be involved in the
change of function or biophysical properties of the encoded protein (reviewed in Inoue and
Lupski, 2002). However, the disease phenotype dominates the normal phenotype only if
DNA variations affect the overall fitness of the organism. A clear relationship between proteins
with an essential in vivo function and damaging phenotype has been observed (Jeong et
al., 2001; Krylov et al., 2003). Moreover, the relatively dispensable proteins evolve more
rapidly during the evolution as deleterious changes to the protein structure and function
are subject to weaker selection (Hirsh and Fraser, 2001).
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2.1 Patterns of Inheritance
The inherited diseases, in which a change in a single gene causes a distinct phenotype,
are characterized as Mendelian syndromes. The pathogenic phenotypes can be further
divided based on the chromosomal location and penetrating effect of the affected gene. In
autosomal dominant disorders a single copy of the mutated gene is sufficient for the
expression of the disease phenotype, such as in Huntington’s disease. In autosomal
recessive syndromes, e.g. cystic fibrosis, only individuals homozygous for the particular
mutant allele or heterozygous for two different alleles develop the disease. Individuals with
one healthy allele are phenotypically normal carriers of the syndrome. Males and females
are equally likely to be affected, whereas sex-linked diseases show different pattern. The
inheritance patterns of mtDNA are unique as the mitochondrial DNA is inherited maternally.
The majority of human genetic disorders, however, are of complex type. Variants in different
parts of the genome together with environmental factors and, for example, aging may lead
to a predisposition to complex diseases such as asthma, diabetes or depression.
2.1.1 Allelic spectra in rare diseases
The rare disorders, such as most Mendelian type diseases, are caused by panoply of
diverse highly penetrable disease alleles with minor allele frequency of less than 1%. As an
example, 461 different mutation types have been identified in the gene encoding for Bruton
tyrosine kinase (http://protein.uta.fi/BTKbase). These mutations lead to an X-linked
agammaglobulinemia (XLA) by disrupting the B-cell maturation process (Sideras and Smith,
1995). The varied mutational spectrum of XLA is typical of X-linked and autosomal dominant
syndromes. The disease-associated alleles are eliminated rapidly by natural selection,
whereas new mutations replenish the disease class leading to a rapid turnover and mutation-
selection equilibrium (Reich and Lander, 2001).
Some recessive autosomal Mendelian diseases may have common alleles as a result of
mild selection against disease alleles or because of selective heterozygous advantage.
Cystic fibrosis is a fairly common disease resulting from a loss or dysfunction of a CF
transmembrane conductance regulator (CFTR) Cl- channel (Riordan et al., 1989). In contrast
to XLA causing mutations, the cystic fibrosis is associated with few common alleles together
with a large number of rare alleles (Estivill et al., 1997). It has been suggested that the
alleles with high frequency are involved with resistance to Salmonella typhi among
heterozygous individuals (Pier et al., 1998).
In addition to heterozygotic advantage, simpler allele spectra may also originate from historic
or geographic reasons. A recent population bottleneck in Finland enriched certain disease
alleles that are rare elsewhere, whereas the number of patients with e.g. cystic fibrosis is
extremely low in the Finnish population (Kere, 2001).
2.2 Databases related to human diseases
In 1957, Ingram described the first defect in the gene encoding for human haemoglobin
leading to severe anemia (Ingram, 1957). The first mutation database for haemoglobin
mutations was published in 1976 (Lehman and Kynoch, 1976). Since then, the number and
variety of databases cataloguing human disease variations has grown enormously. Majority
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of disease-causing mutations still exist in locus-specific databases maintained by the
laboratories or consortia studying the gene affected. However, several generic mutation
databases have emerged as a result of incompatible database formats for large-scale
mutation analyses.
2.2.1 Locus-specific databases
The locus-specific databases can be categorized as mutation or patient based registries
(Claustres et al., 2002). Both registries typically include a unique identifier for the disease
allele and reference(s) either to the published article or submitting physician. The effect of
the disease-causing mutations is described from the genomic DNA level through mRNA to
protein level. The patient based databases also include information related to the phenotype,
family history, patient data and response to treatment (Lappalainen et al., 1997). The most
comprehensive listing of locus-specific databases is available from the Human Genome
Variation Society web site.
The information and registry formats have gone through many changes during the last 15
years. The recommendations for the description of a particular mutation (den Dunnen and
Antonarakis, 2001) or database format (Scriver et al., 1999) by the Human Genome Variation
Initiative have united the field and allowed development of several generic tools for the
maintenance and analyses of the databases. The Mutation Storage and Retrieval (MuStar)
(Brown and McKie, 2000), Universal Mutation Database (UMD) (Beroud et al., 2000) and
MUTbase (Riikonen and Vihinen, 1999) software have been successfully applied to create
a number of locus-specific databases. Importantly, the database format for describing the
mutation and various clinical data is highly structured in all programs permitting high data
integrity. The programs verify that the submitted or manually included data refers to the
correct position in the right reference sequence; a welcomed feature as the published
patient data often includes errors at all levels. The UMD and MUTbase programs also
generate several web pages showing statistical analyses of mutations in the corresponding
gene or distribution of the mutation types at the exon/intron or protein domain levels. The
MuStar and UMD distribute data either in spreadsheets or in relational database format,
whereas MUTbase generates flat files. Another essential tool for searching data from various
databases simultaneously and analyses is the Sequence Retrieve System (SRS) (Zdobnov
et al., 2002). In SRS 3D, sequence features extracted from other databases can be
simultaneously mapped onto structures. All the described programs are flexible and allow
addition of tailored tools e.g. using Bioperl or The European Molecular Biology Open Software
Suite (EMBOSS) (Rice et al., 2000; Stajich et al., 2002).
Today, analyses of disease-causing mutations include either a large number of mutations
in a single affected gene or thousands of mutations from several different locus-specific
databases. At the same time, the number of publications describing individual mutations
has decreased leading to an increasing number of deposited mutations in the databases
that are not publicly available. Roughly 4% of the mutations leading to various
immunodeficiencies are hidden in the locus-specific databases. The number of confidential
mutations is likely to vary according to the disease prevalence and curating database
consortia as large estimates have been described for other diseases (Cotton, 2000).
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2.2.2 General databases
In contrast to locus-specific databases, common repositories contain less detailed
information of mutations from multiple loci. The Mendelian Inheritance in Man (MIM) was
the first attempt to list all the inherited monogenic human diseases (McKusic, 1998). The
current online version (OMIM) is available at the National Centre for Biotechnology
Information website. OMIM only lists the most important or first mutation(s) identified in the
corresponding disease. Hence, a second attempt to catalogue quantitatively all types of
DNA variations associated with diseases was initiated by Cooper and Krawczak in 1990.
The Human Genome Mutation Database (HGMD) is comprehensive collection of all types
of germline mutations associated with human inherited diseases. The current version of
HGMD contains 39415 different mutations affecting 1516 genes (Stenson et al., 2003).
Each mutation has been logged only once to the database to avoid the problem of separating
recurrent lesions from mutations identified in a descent. As these two main depositories
contain only nuclear mutations, the human mitochondrial disease related mutations are
collected into e.g. MITOMAP (Kogelnik et al., 1998).
Somatic mutations have also been collected into several databases. The largest of them
describes almost 19 000 tumorigenic TP53 mutations from a gene encoding for p53 protein.
The tumour suppressor function of p53 protein is lost in more than half of human cancers.
75% of these mutations occur as missense mutations rather than deletions, insertions or
frameshifts (Olivier et al., 2002).
2.2.3 Disease-centred platforms
The primary immunodeficiencies (PIDs) are a group of mainly rare syndromes affecting
the function of immune system. As a result, patients with these intrinsic defects have
increased susceptibility to recurrent and persistent infections. More than 100 different PIDs
have been classified and a large number of disease-associated variants collected into a
central registry by the European Society for Immunodeficiencies (ESID) or locus-specific
databases (Fahrer et al., 2001; Vihinen et al., 2001).
As the symptoms of several PIDs are similar, the diagnosis is still largely based on analysis
of the genetic defect(s). After correct diagnosis, however, many patients may live quite
normal life, e.g. intravenous immunoglobulin can be used for treatment in XLA. Recently,
the Immunodeficiency Diagnostics registry (IDdiagnostics) and Immunodeficiency Resource
(IDR) were developed to help physicians to contact laboratories analysing these rare genetic
defect(s), as well as to collect verified information related to immunodefiencies (Väliaho et
al., 2002; Samarghitean et al., 2004). As rapidly accumulating information from the HGP
has lead to cloning of a large number disease associated genes, knowledge bases providing
curated information of a particular disease for scientists, physicians and patients are likely
to become more important than locus-specific or generic databases.
2.3 Cellular mechanisms behind mutations
DNA is a reactive molecule modified continuously by a range of chemicals and enzymes
inside the cell nucleus or mitochondria. Exogenous agents, such as UV radiation or chemical
carcinogens in food, may induce variations at the DNA level. However, majority of the
inherited disease-causing mutations are caused by errors in the endogenous procedures
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involved in genomic stability (Cooper and Krawczak, 1993). Cells have an extremely efficient
capacity to suppress the generation of alterations to the DNA sequence. Errors escaping
the proofreading machinery become substrates of mismatch, base extinction or nucleotide
extinction repair systems (Jiricny, 1998). The efficiency and specificity of these processes
is DNA sequence dependent (Cooper and Krawczak, 1993). As a result, variations occur
non-randomly throughout the genome and each type of variation shows a pattern of hotspot
and cold-spot sites in a given sequence.
The spectrum of single-base-pair substitutions in the HGMD was found to be highly
hierarchical in their propensity to undergo substitution. The transitions (e.g. where a purine
is substituted by a another purine) and transversions (e.g. where purine is substituted by a
pyrimidine) occur at frequencies of 62,5% and 37,5%, respectively (Krawczak et al., 1998).
The CpG transversions comprise 23% of all human hereditary disease-associated mutations
(Waters and Swann, 2000). Furthermore, the mutation site is clearly affected by its
surrounding nucleotide sequence, though it extends only by a few bases. A clear bias for
the immediately flanking nucleotides for most of the 12 possible changes was shown
(Krawczak et al., 1998).
The molecular mechanisms of spontaneous mutagenesis occurring during replication,
recombination and repair processes were first investigated in bacteria and yeast (reviewed
in Maki, 2002). The genes involved have then been shown to be highly conserved among
various organisms (Reenan and Kolodner, 1992; Morrison and Sugino, 1994). Based on
the genetic, biochemical and structural results, several models of how spontaneous
mutations arise have been introduced.
2.3.1 Misincorporation
An insertion of a non-complementary nucleotide at the end of the primer by DNA polymerases
results in a single nucleotide change (Figure 2A). There are at least three possible check
points for the proper geometric alignment during base insertion: initial dNTP binding and
forming of correct hydrogen bonds based on the Watson-Crick model (Galas and
Branscomb, 1978; Clayton et al., 1979), selection for the correct geometry after binding of
the dNTP by an induced-fit mechanism (Echols, 1982; Kuchta et al., 1987; Kuchta et al.,
1988; Sloane et al., 1988; Wong et al., 1991), and the chemical step leading to formation of
phosphodiester bond. Insertion of a non-complementary nucleotide has been shown to
restrain primer extension, thereby allowing translocation of the primer terminus into the
active site of the proofreading 3’->5’ exonuclease (Kunkel and Bebenek, 2000).
The DNA polymerases differ in their interactions with the minor groove of the template-
primer duplex and there are significant differences in the extent to which different
polymerases use methods for recognizing the correct nucleotide. In some cases a non-
complementary nucleotide may by-pass the proofreading. The efficiency of the proofreading
varies as a function of the mismatch type and the sequence context in which it is embedded
(10-5 to >10-8)(Kunkel and Bebenek, 2000). For example, the common G/T mispair is
stabilized by two hydrogen bonds causing only a small distortion in the helical structure of
the DNA (Hunter et al., 1987). Local imbalances of dNTP pools have also been shown to
increase the probability of misincorporation and lead to a disease phenotype (Bebenek et
al., 1992; Martomo and Mathews, 2002; Song et al., 2003). In addition, the dNTP pools
may be contaminated with unnatural nucleotides as oxygen radicals attack free nucleotides
more readily than double helical DNA (Park et al., 1992). One such compound, 8-oxodGTP,
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can be inserted opposite to either cytosine or adenine of template DNA with almost equal
efficiency resulting G/C to A/T tranversion during the next DNA replication process (Maki
and Sekiguchi, 1992).
2.3.2 DNA Slippage
In 1966 Streisinger proposed a hypothesis for transient misalignment of the primer and
template during the polymerization process (Sreisinger, 1966). This premutational
intermediate is stabilized by correct base pairs between the nucleotides surrounding the
misaligned nucleotide (Figure 2B). The following polymerization leads to a deletion if the
unpaired nucleotide is in the template strand. An insertion occurs if the unpaired nucleotide
is located in the primer strand. The error rates for insertion and deletion increase as the
length of the repeating sequence increases. The opposite has been observed if the repeats
are either interrupted or eliminated (Kunkel, 1985; Bebenek et al., 1993). A strand slippage
may also lead to a single nucleotide substitution if the slippage is followed by a
complementary nucleotide incorporation and immediate realignment before further
polymerization (Figure 2C).
The initiation of template-primer slippage may occur via multiple pathways. The extension
of the primer from a non-complementary nucleotide is highly inefficient (Benkovic and
Cameron, 1995). Therefore, Kunkel suggested that primer relocation might occur after
misinsertion to create correct terminal base pairing that allows further polymerization (Kunkel
and Soni, 1988). This model is not limited to single-base pair errors and may occur at any
template location. In a similar way, damaged templates might also cause frameshift by
primer relocation. The model is supported by studies with several polymerases with different
lesions (Schaaper et al., 1990; Lambert et al., 1992; Garcia et al., 1993). Slippage may
also occur during enzyme dissociation or reassociation as has been observed for the
polymerases with low processivity (Kunkel, 1985; Kunkel, 1986). Short deletions or insertions
comprise the second most common type of mutation associated with human inherited
diseases. In the HGMD, all gene deletions either overlap or flank with a two base pair
repeat (Antonarakis et al., 2000).
2.3.3 Deamination of methylcytosine into thymine
In eukaryotic genomes, the methylated cytosines predominantly occur in the CpG
dinucleotide (Bird, 1999). This dinucleotide undergoes germline transition to TpG (and
CpA in the complementary strand) at frequencies six to seven times the base mutation rate
(Cooper et al., 1995) as a result of spontaneous deamination of methylcytosine (Figure
2D). Although two human thymine DNA glycosylases have been identified, this repair pathway
is clearly inadequate (Brown and Jiricny, 1987; Hendrich et al., 1999). Subsequently, CpG
dinucleotides are only present at 20% of the expected frequency in human genome (Brown
and Jiricny, 1987; Hendrich et al., 1999).
The CpG dinucleotides are significantly biased by the 5’ flanking nucleotide on the non-
coding DNA strand, whereas the nucleotide immediately downstream of CpG is significant
irrespectively of the strand (Krawczak et al., 1998). The methylated cytosines are also
known to occur within CpNpG triplets (where N is any nucleotide) at low frequency
(Woodcock et al., 1988; Clark et al., 1995; Kay et al., 1997). The CpApG trinucleotide was
shown to undergo transition to TpApG at a 50% higher rate than any other triplet on both
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strands (Krawczak et al., 1998). The data clearly indicate biased nucleotide neighbourhood
surrounding the methylated CpG dinucleotide in human inherited diseases. However, the
frequency of CpG mutations may differ between the male and female germ-lines owing to
profound differences in DNA methylation. The oocyte DNA is markedly undermethylated,
whereas sperm DNA is heavily methylated (Monk et al., 1987; Rideout et al., 1990).
Figure 2. Proposed reaction mechanisms for mutations. A - incorporation of incorrect dNTP to the template. B
- DNA slippage as a result of misalignment and correct incorporation. C - Mispairing initiated first by misalignment
and followed by a correct incorporation and realignment of the polymerized DNA strand. D - Spontaneous
deamination of 5’methylcytosine results in thymine. The figure was adapted from (Cooper and Krawczak,
1993).
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2.4  Pathogenic variations affect biophysical properties of proteins
DNA variations located at the gene loci may cause pathological consequences by either
affecting the cell specific expression profile or biophysical properties of the encoded protein.
Currently, variations found in the regulatory positions comprise less than 1% of the inherited
disease-causing mutations deposited in the HGMD. The number of these mutations is
likely to increase together with our understanding of complex diseases and gene regulation.
Changes leading to a loss or increase in number of active genes, such as an extra
chromosome in Down syndrome, or complex rearrangements and large deletions spanning
the whole disease loci, cover only 8% of disease-causing mutations registered in the HGMD.
Vast majority of somatic and inherited pathogenic mutations are, therefore, small deletions
and insertions or point mutations located at the protein-coding region (Olivier et al., 2002;
Stenson et al., 2003). These genetic alterations specifically influence the features of the
encoded polypeptide.
2.4.1 Characteristics of pathogenic SNPs
The nucleotide diversity at the coding sequence is dependent on the functional class of a
SNP. The silent SNPs show approximately 2.5 times more diversity compared to that of
nonsynonymous SNPs (Cargill et al., 1999; Halushka et al., 1999). In the majority of the
non-synonymous SNPs, the minor allele frequency falls below 5% (Cargill et al., 1999;
Stephens et al., 2001). The non-conservative SNPs leading to a dramatic change or
termination codon have the lowest minor allele frequencies and the natural selection clearly
acts against them (Figure 3B).
In most databases, the effect of a disease-causing SNP on the mRNA or on the protein
level is predicted directly from the genomic DNA analyses. Translationally silent mutations
have been shown to occur rarely (Figure 3A) and are assumed to affect mRNA splicing
(e.g. Sumazaki et al., 2001). Although missense and nonsense mutations have also been
shown to cause aberrant splicing, these SNPs are generally interpreted to change only the
affected codon (reviewed in Cartegni et al., 2002). Point mutations introducing a premature
termination codon are removed by nonsense-mediated mRNA decay (Maquat, 2002),
whereas missense mutations accumulate to human genome depending on the
consequences to the protein function, thermodynamic stability and folding in vivo.
Figure 3. A - Natural selection acts against mutations with an increasing radical effect on the protein structure.
B - The substitutions identified from the pseudogenes and SNPs at the exons were analysed based on
Grantham’s scale (Grantham, 1974) (I = silent, II conservative, III moderately conservative, IV moderately
radical, V radical, and VI nonsense). The figure was created by using data from the HGMD database and
results either described or referred in (Stephens et al., 2001).
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2.4.2 Pathogenic mutations affect conserved positions
Several methods have been applied to analyse the differences between pathogenic and
non-pathogenic missense mutations at the protein level. These methods have implemented
sequence entropy together with various structural parameters derived from experimental
structures (Sunyaev et al., 1999; Chasman and Adams, 2001; Ng and Henikoff, 2001;
Ferrer-Costa et al., 2002; Saunders and Baker, 2002; Shen and Vihinen, 2004) or developed
simple rules for predicting damaging amino acid substitutions (Sunyaev et al., 2001; Wang
and Moult, 2001; Steward et al., 2003).
The disease-causing mutations are over-abundantly located at conserved positions, whereas
normal variation is more randomly distributed (Miller and Kumar, 2001). At the secondary
structural level, the normal variations are located in the exposed (solvent accessible surface
>5%) α-helical and coil structures, whereas disease-associated substitutions are more
likely to occur in the buried structures (Ferrer-Costa et al., 2002; Steward et al., 2003).
Interestingly, 83% of disease-associated mutations were predicted to affect the protein
stability whereas majority of the normal variations had no influence when similar rules were
applied (Wang and Moult, 2001). Analysis of 63 disease associated protein structures
assigned a functional role for only 29% of the analysed disease-causing mutations (Steward
et al., 2003). Recently, pathogenic mutations were also shown to affect covariantly conserved
positions (Shen and Vihinen, 2004).
The mutation types also differ between the disease variations and substitutions occurring
between species or non-pathogenic SNPs (Miller and Kumar, 2001). There is a clear negative
selection against SNPs leading to dramatic changes at the protein sequence based on the
Grantham’s physico-chemical score (Grantham, 1974; Cargill et al., 1999; Halushka et al.,
1999; Stephens et al., 2001). The difference in physico-chemical properties of amino acid
substitutions affecting the phenotype is larger for disease-associated substitutions (Figure
3B). The most severe substitutions were not observed, as they are more likely to result in
lethal phenotypes (Miller and Kumar, 2001; Steward et al., 2003). The severity of the
substitution has also been shown to correlate with the likelihood of observing patients
clinically (Krawczak et al., 1998).
2.4.3 Two roads to disease
Protein evolution is primarily governed by protein function. As a result, proteins must be at
least marginally stable and fold fast enough to prevent aggregation. Based on their structural
consequences, disease-causing mutations can be categorized into two main classes: loss
of protein function, which is often accompanied by improper localization and rapid
degradation of defective product, and, mutations causing the pathological phenotype by
affecting thermodynamic stability or kinetic pathway of the mutated protein. In this case the
disease is generally associated with toxic properties of aggregation-prone folding
intermediate (reviewed in Gregersen et al., 2000).
Disease-causing mutations influencing the balance between folding and misfolding pathways
are likely to affect proteins with already small kinetic preferences for the folding pathway.
One such protein is CFTR, where mutations have been shown to cause cystic fibrosis by
impairing folding and biosynthetic processing of nascent molecules (reviewed in Kopito,
1999). However, maturation of wild-type CFTR protein has also been shown to be inefficient,
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less than 50% of synthesized CFTR folds correctly during its passage to the cell surface
(Ward and Kopito, 1994).
The result of a missense mutation to protein structure and function, however, cannot be
predicted simply by sequence entropy as has been illustrated for p53 mutations. Majority
of somatic mutations affecting TP53 gene are located in the DNA-binding domain, with six
hot spots clustering to the DNA-binding surface, and three residues involved in binding of
Zn2+ (Bullock et al., 2000). Based on the crystal structure, two of the residues at the DNA-
binding surface contact DNA directly and four stabilize the surrounding structure (Cho et
al., 1994). Mutations removing crucial interactions between the protein and its ligand had
no effect on protein folding, but failed to bind an artificial p53 specific promoter DNA
sequence. The reduced protein stability and capacity to bind DNA by the four other functional
mutations varied. In contrast, mutations affecting hydrophobic core or Zn2+ binding residues
destabilized the protein structure dramatically (Bullock et al., 2000). Interestingly, a number
of core mutations could still bind DNA with 40-80% of the wild-type affinity. It may be possible
to rescue these mutations by binding of a small molecule (reviewed in Bullock and Fersht,
2001), whereas functional mutations would all require their own ligand.
2.4.4 Theoretical and experimental analyses of missense mutations
Currently, there is no de novo method to calculate the correct three-dimensional structure
of a protein from its primary sequence. Small perturbations caused by amino acid
substitutions, however, can be predicted by using molecular modelling and molecular
dynamic simulations from an experimentally solved structure (Leach, 2001). Comparative
modelling exploits the structural similarities between proteins by constructing a three-
dimensional structure based upon the known structure of one or more related proteins. In
molecular dynamic simulations, successive configurations of the system are generated by
integrating the Newton’s laws of motion. The calculations are broken into a series of very
short time steps (1-2 femtoseconds), and forces acting on each atom are recalculated at
each step by using empirical force field. The resulting trajectory specifies the positions and
velocities of the particles in the system as a function of time. However, there are limitations
of how far consequences of missense mutations to the protein structure can be predicted.
The current bioinformatical methods rely heavily on structural and biophysical data of a
relatively small number of model proteins.
Protein folding occurs through an ensemble of structures that are transiently occupied and
share an increasing number of wild-type contacts towards the native conformation (Fersht,
2002). The role of a particular position in protein folding can be studied by using φ-value
analyses (Fersht et al., 1992), where a number of non-disruptive mutations removing specific
interactions are created in several positions of the analysed protein. The value of φ is
defined as a ratio of change in transition state energy compared to the change in stability
on mutation. The difference in transition state energy on mutation can be analysed by
measuring the folding rates of wild type and mutated proteins. Positions sharing wild type
interactions have φ-values close to one as the mutation affects the transition state and wild
type conformation identically. Protein denaturation by heat or chemical denaturants, such
as guanidine hydrochloride and urea, is used for measuring the stability. The change in
protein structure is typically monitored by using fluorescence or circular dichroism
spectroscopy. The structure of the denatured and native states can be obtained with NMR
spectroscopy or X-ray crystallography.
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3 SH2 DOMAINS
At present, the results of mutations at the protein level are typically described as amino
acid substitutions predicted directly from the genomic DNA analyses. To analyse the
structural and functional consequences of pathogenic mutations at the protein level, we
have concentrated on a distinct well-characterized protein domain family. The Src homology
2 (SH2) domains are about 100 residues in length. More than 100 different SH2 domains
have been identified or predicted with an average of 28% pairwise residue identity (Pawson
et al., 2002, Pfam code PF00017). SH2 domains mediate intramolecular recognition and
intermolecular protein-protein association almost invariably by binding to phosphorylated
tyrosine residues in specific sequence contexts. Structures of many individual SH2 domains
have been solved and their binding to ligand studied (reviewed in Kuriyan and Cowburn,
1997). A number of disease-causing mutations have been described from the SH2 domains.
3.1 SH2 domain function
Tyrosine phosphorylated (pY) regions in proteins function as specific binding sites for the
SH2 domains containing cellular signalling proteins. Binding of SH2 domains to their in
vivo targets recruits the SH2 domain-containing protein to its proper signalling complex
regulating downstream signalling cascades (reviewed in Schlessinger and Lemmon, 2003).
In addition to their role in assembling activated complexes, particular SH2 domains are
involved in intramolecular interactions that control enzyme activity. A loop from the N-terminal
SH2 domain binds to the catalytic cleft of the phosphatase domain in the same SHP-2
molecule leading to an autoinhibited configuration (Hof et al., 1998). The Src SH2 domain
has been shown to bind a phosphorylated tyrosine at the C-terminus of the same molecule
resulting inactivation of enzyme activity by rearrangement of catalytic center in the kinase
domain (reviewed in Hubbard et al., 1998). In both examples, the high affinity ligands can
compete with the intramolecular interactions and release the catalytic domains for their in
vivo targets.
3.2 SH2 domain structure
Structures of a significant number of SH2 domains both in isolation and bound to various
target molecules have been determined by X-ray crystallography and NMR spectroscopy.
All the analysed SH2 domains have a typical SH2 domain fold consisting of a large anti-
parallel β-sheet sandwiched between two α-helices The central β-sheet divides the domain
into two functionally separate sides. The αA-helix borders the face binding to
phosphotyrosine. Residues from αB-helix and the EF and BG-loops are involved in binding
of side chains C-terminal to phosphotyrosine in the ligand. The βD’, βE and βF strands
form an additional β-sheet that closes off one part of this side (Figure 4 and the notation
used for describing the secondary structures).
3.2.1 Residues involved in ligand-binging
The ligand binds in an extended conformation lying across the surface of the domain
orthogonal to the central β-sheet in most experimentally solved SH2-ligand structures.
SH2 domains make specific interactions with the phosphotyrosine and 3-6 residues
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immediately following it (reviewed in Kuriyan and Cowburn, 1997). There are only limited
contacts formed between the domain and the side chains of the ligand residues upstream
from the phosphorylated tyrosine, apart from SHP-2 and SH2D1A (Huyer et al., 1995; Poy
et al., 1999).
The residues interacting with phosphotyrosine are generally conserved and form a positively
charged binding pocket on the SH2 domain surface (reviewed in Kuriyan and Cowburn,
1997). The only invariant residue among the SH2 domains, an arginine at the fifth position
of βB strand (and therefore coded as RβB5), extends from the bottom of the pocket to
recognize the phosphate group from the phosphotyrosine. This interaction determines the
binding specifically to phosphotyrosines as the arginine side chain is not long enough to
interact with phosphorylated serine or threonine.
Figure 4 - A ribbon model of the SH2 domain of SH2D1A (PDB code 1D1Z). The large β-sheet (blue) is flanked
by two α-helices (red). The secondary structures are indicated as was first introduced in (Eck et al., 1993).
The residues involved in binding of the third residue following pY (pY+3) are located in EF-
and BG-loops. These residues are highly variable and respond to individual SH2 domain
specificity. In the SH2 domain of the Src tyrosine kinase, the ligand-binding residues come
close together forming another binding pocket on the SH2 domain surface. The majority of
SH2 domains bind to their ligands as Src SH2 domain. In two phosphatase enzymes, SHP-
2 and phospholipase Cγ-1 (PLCγ-1), the ligand-binding residues move away from each
other opening up a binding groove on the SH2 domain surface (Lee et al., 1994; Pascal et
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al., 1994). The interactions between the ligand and SH2 domains extend beyond pY+3
position. In the structure of N-terminal SH2 domain of SHP-2 complexed with a ligand, the
phenylalanine side chain at the pY+5 position in ligand is bound between BG and EF loops
closing the isoleusine at the pY+3 position.
3.3 SH2 domain specificity
The SH2 domains bind to their ligands with only modest affinities. The dissociation constants
range from 0.2 to 5 µM for SH2 domain-ligand interactions, whereas SH2 domains have
been shown to associate with a random peptide only 10-fold lower affinity (Piccione et al.,
1993; Ladbury et al., 1995). Unphosphorylated peptides do not bind to SH2 domain, with
the only known exception of SH2D1A (Lemmon and Ladbury, 1994; Hwang et al., 2002).
Furthermore, the phosphotyrosine alone shows very weak association (Kd > 1mM).
Figure 5. Domain organization of the defected proteins. Pleckstrin homology (PH); Tec homology (TH); Src
homology 3 (SH3) and Ras GTPase activating (RASA1) domain. SH2 domains with disease-causing mutations
are shown with an asterisk.
The specificity in vivo may be increased dramatically as a result of cooperative binding
together with other signalling domains in the same molecule. PI3K, Zap-70, Syk, SHP-2
and PLCγ-1 contain two SH2 domains separated by a linker of varying length. All five
proteins have been shown to associate with a conserved tyrosine-based activation motif
(ITAM) in the cytoplasmic tail of different receptors. The binding of biologically relevant
ITAM showed Kd of 0.3-3.0 nM, whereas alternative ITAMs were bound with 1000-10000-
fold lower affinity (Ottinger et al., 1998). Recent work has also demonstrated the role of
water molecules at the Src SH2 domain-ligand interface (Chung et al., 1998; Henriques
and Ladbury, 2001).
Majority of the peptide motifs interacting with SH2 domains have been identified by using in
vitro oriented phosphopeptide library assays (Songyang et al., 1993; Songyang and Cantley,
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1995). Based on these results, together with structural analyses of different ligand-binding
models, it is apparent that SH2 domains bind distinct but overlapping sequence motifs.
The selectivity of an individual SH2 domain is not sharply defined, and a range of residues
is typically tolerated at each site following the phosphotyrosine. Supporting these findings,
different SH2 domains have been shown to compete for same binding target in vivo (e.g.
Nishimura et al., 1993; Sayos et al., 2001).
3.4 Diseases related to SH2 domains
Mutations in the SH2 domains of Bruton tyrosine kinase (BTK), SH2D1A, Ras GTPase
activating protein (RASA1), Zap-70, SHP-2 and the p85α subunit of the PIP3 kinase (PI3-
K) cause nine distinct clinical phenotypes (Table 2). The domain organization of the proteins
is given in Figure 5. Currently, 168 unique molecular events in 325 unrelated patients have
been reported. The mutation types range from large gross deletions of the whole gene to
single point mutations. Missense mutations comprise the most common mutational event
(57%). Previously, proteins with an essential function have been shown to possess a more
damaging phenotype (Jeong et al., 2001; Krylov et al., 2003). In agreement, proteins with
defective SH2 domains either have a crucial role during cell development process or regulate
multiple signaling cascades.
Table 2. Diseases related to SH2 domainsa.
a
 not available.
The majority of the disease-causing mutations are found in BTK, SH2D1A and SHP-2.
Analyses of missense mutations in these proteins have provided information of functionally
and structurally important residues (Tzeng et al., 2000; Morra et al., 2001b; Hwang et al.,
2002; Li et al., 2003a). However, no correlation has been described between the type and
position of the mutations and clinical XLA (Vihinen et al., 1999) or XLP phenotype (Engel et
al., 2003). In fact, identical mutations within the family have been shown to result in different
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phenotype (Kornfeld et al., 1997; Coffey et al., 1998; Nichols et al., 1998; Sumazaki et al.,
2001). Furthermore, defects in BTK or SH2D1A have been mistakenly diagnosed with
common variable immunodeficiency (CVID) (Spickett et al., 1997; Morra et al., 2001a;
Nistala et al., 2001; Arico et al., 2002). CVID is the most common primary immunodeficiency
with a highly heterogeneous clinical presentation and unknown genetic basis (Conley et
al., 1999). Mutations in BTK and SH2D1A show a typical X-linked inheritance pattern without
any genetic heterogeneity, and emphasize the importance of understanding how genetic
defects cause clinical phenotype at the protein level.
On the contrary, mutations in PTPN11 encoding the SHP-2 protein have been shown to
cause at least four distinct diseases. The clinical and genetic heterogeneity of these disorders
suggests a possible relation between different PTPN11 mutations and distinct clinical
features. Analyses of large cohort of individuals with Noonan syndrome (Tartaglia et al.,
2001; Tartaglia et al., 2002) showed that PTPN11 mutations are more likely to be found
when pulmonary stenosis is present, whereas hypertrophic cardiomyopathy is less prevalent
among these patients. In another study, this correlation was not found (Sarkozy et al.,
2003). However, the location of mutations within the PTPN11 gene correlated with different
heart defects in Noonan and LEOPARD syndromes.
3.4.1 Mutations in BTK lead to X-linked agammaglobulinemia
BTK participates in immune cell signal transduction pathways regulating activation,
proliferation, differentiation and apoptosis with the exception of T lymphocytes (Smith et
al., 2001). Mutations in all five domains of BTK have been shown to cause X-linked
agammaglobulinemia (XLA) by disrupting the pre-B cell receptor signal cascade (reviewed
in Kurosaki, 2002). As a result, B-cell maturation is arrested between pro- and pre-B-cell
stages and the complete lack of mature B-lymphocytes leads to extreme susceptibility to
bacterial infections in patients (reviewed in Vihinen et al., 2001).
Although BTK has been shown to associate with a large number of proteins (Smith et al.,
2001), the SH2 domain has been reported to interact only with the B-cell linker protein
(BLNK) in vivo (Hashimoto et al., 1999; Su et al., 1999). B-cell receptor (BCR) engagement
leads to phosphorylation of several BLNK tyrosines and, thereby, formation of an active
complex as BTK, PLCγ2, Grb2 and Vav bind to BLNK. Recruitment of BTK and PLCγ2
proteins close together allows BTK to phosphorylate PLCγ2, which then leads to a sustained
calcium release from the storage vesicles (Fluckiger et al., 1998). Calcium concentration
has various general effects in B-lymphocytes e.g. regulation of transcription factors related
to proliferation (Tan et al., 2001). Furthermore, BCR stimulated B-cells from XLA patients
did not show elevated calcium mobilization (Genevier and Callard, 1997). Currently, 58
different XLA mutations in 102 patients have been reported from the SH2 domain (http://
bioinf.uta.fi/BTKbase).
3.4.2 Genetic cause of X-linked Lymphoproliferative Disease
SH2D1A is a small lymphocyte-specific signalling molecule that is defective or absent in
patients with X-linked Lymphoproliferative Disease (XLP) (Coffey et al., 1998; Nichols et
al., 1998; Sayos et al., 1998). Unlike typical signalling proteins, SH2D1A is comprised of a
single SH2 domain followed by a short tail. A total of 100 disease-causing mutations have
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been reported from 85 unrelated families (http://bioinf.uta.fi/SH2D1Abase). All missense
mutations affect the SH2 domain.
SH2D1A has a dual role in regulation of the initial signal transduction events induced by at
least six members of the SLAM (signal lymphocyte-activator molecule) family of cell-surface
receptors. These receptors function in the immune synapse, between T lymphocytes or
natural killer cells and antigen presenting cells (reviewed in Engel et al., 2003). SH2D1A
binds to the cytoplasmic tail of SLAM family receptors through a conserved T-(I/V)-pY-X-X-
(V/I) motif (where X is any amino acid). The structural basis for the specific recognition of
SLAM by SH2D1A has been unravelled by both X-ray crystallography and NMR methods
(Poy et al., 1999; Hwang et al., 2002). In addition to conventional SH2-ligand interactions,
SH2D1A forms also specific interactions to the residues preceding the phosphotyrosine in
the ligand. These interactions allow this protein to bind SLAM receptor independently of its
phosphorylation status, and thereby, block the recruitment of SH2-containing signal-
transduction molecules, such as SHP-2 (Sayos et al., 1998; Sayos et al., 2001). SH2D1A
has also been shown to function as an adaptor molecule. The SH2 domain surface formed
by positively charged residues in βF strand, N-terminal end of the αB helix and the intervening
loop associates with an electrostatically complementary interface on the Fyn SH3 domain.
Furthermore, the buried surface does not involve the phosphotyrosine binding site, whereas
the bound surface on the SH3 domain overlaps the surface that is expected to participate
in auto-inhibitory interactions in the Fyn kinase (Latour et al., 2001; Chan et al., 2003;
Latour et al., 2003; Li et al., 2003b). The interaction between these domains results in
recruitment of an active Fyn kinase close to active receptors in the immune synapse, and
subsequently, phosphorylation of tyrosines in the cytoplasmic tails of these receptors. A
number of missense mutations locate on the conventional ligand-binding surface, whereas
none have been found from the Fyn binding surface. However, mutations leading to unstable
SH2D1A may cause XLP by preventing the initial mechanism in which an adaptor molecule
is required to link a receptor devoid of intrinsic catalytic activity to a cytoplasmic tyrosine
kinase.
3.4.3 Mutations affecting ZAP-70
ZAP-70 protein consists of two SH2 domains followed by a C-terminal kinase domain.
Association with both SH2 domains to the ζ chain of activated T cell antigen receptor
(TCR) have been shown to regulate multiple downstream pathways after receptor activation
(Chan et al., 1992). Genetic alterations in the ZAP-70 gene lead to an extremely rare
autosomal recessive form of severe combined immunodeficiency (SCID), also named as
ZAP-70 deficiency. Only one of the reported fourteen patient mutations affects αB helix of
the N-terminal SH2 domain (http://bioinf.uta.fi/ZAP70base). Although, the mutated protein
associated with the ζ chain of TCR in a wild type manner in vitro, it is degraded rapidly in
vivo (Matsuda et al., 1999). The loss of ZAP-70 function leads to selective inability to
produce CD8+ T lymphocytes and abolishes TCR stimulation in mature CD4+ T lymphocytes
(Arpaia et al., 1994; Elder et al., 1994). ZAP-70 deficiency is ultimately fatal unless patients
undergo bone marrow transplantation.
Recently, a spontaneous missense mutation in the βB strand of C-terminal SH2 domain
was shown to cause chronic autoimmune arthritis in mice that resembles human rheumatoid
arthritis (Sakaguchi et al., 2003). Altered signal transduction from T-cell antigen receptor
through the aberrant ZAP-70 is likely to change the threshold of T lymphocytes to thymic
selection, leading to positive selection of otherwise negatively selected autoimmune T cells.
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3.4.4 PI3K mutation is associated with severe insulin deficiency
Phosphatidylinositol 3-kinase (PI3K) plays a pivotal role in signal transduction pathways
linking insulin with many of its specific cellular responses, including GLUT4 vesicle
translocation to the plasma membrane and inhibition of glycogen synthase kinase-3
(Shepherd et al., 1998). Moreover, PI3K is necessary for the insulin-stimulated increase in
glucose uptake, and glycogen synthesis in insulin-sensitive tissues (Holman and Kasuga,
1997). The structure of PI3K is heterodimeric, consisting of a catalytic subunit (p110) and
a regulatory subunit (p85α) (Antonetti et al., 1996).
Recently, a missense mutation was found in the N- terminal SH2 domain of p85α leading
to severe insulin resistance (Almind et al., 2002). The R409Q mutation is located in the C-
terminus of αB helix, and is not involved in the normal ligand-binding surface. However,
when binding of N-SH2 domain with mono and double phosphorylated ligands was studied
with NMR spectroscopy, the doubly phosphorylated peptide showed nearly 10-fold higher
binding to the isolated SH2 domain. From the NMR structure, it appears that the second
phosphotyrosine is coordinated by the residues in BG-loop and C-terminal part of the αB-
helix (Weber et al., 2000).
3.4.5 Sporadic mutations leading to Basal-cell carcinoma
Basal-cell carcinoma (BCC) is the most frequent skin cancer in the white population (Miller,
1991). BCCs mostly occur sporadically in relation to sun exposure, although their incidence
is increased significantly in some rare genetic disorders (Gorlin, 1987; Bodak et al., 1999).
Somatic mutations at the phosphotyrosine-binding pocket of the C-terminal SH2 domain of
GTPase-activating protein RASA1 have also been found in a subset of BCCs (Friedman,
1995). RASA1 acts by enhancing the intrinsic GTPase activity of Ras, leading to hydrolysis
of bound GTP to GDP and down regulation of Ras activity (Gold et al., 1993; Lazarus et al.,
1993; Scheffzek et al., 1998). The structure of the defective SH2 domain has not been
solved.
3.4.6 Mutations affecting PTPN11 gene
Mutations in the PTPN11 have been found from patients suffering from Noonan syndrome
(NS), LEOPARD syndrome or juvenile myelomonocytic leukaemia (JMML) (Tartaglia et al.,
2001; Digilio et al., 2002; Tartaglia et al., 2002; Loh et al., 2003). The gene encodes SHP-
2 protein, a ubiquitously expressed cytosolic non-receptor tyrosine phosphatase (PTP).
SHP-2 is a key molecule in the cellular response to growth factors, hormones, cytokines
and cell adhesion molecules (reviewed in Neel et al., 2003).
The SHP-2 is composed of two tandem N-terminal SH2 domains, a PTP domain, and a C-
terminal tail. The structural data revealed the functional role of the N-terminal SH2 (N-SH2)
domain in regulating the enzyme activity. The D’E loop and flanking βD’ and βE strands of
the N-SH2 domain extend deep into the catalytic cleft of the PTP domain blocking the
enzyme active site. An intricate intra- and interdomain hydrogen-bonding network together
with charged interactions stabilize the D’E loop conformation in the enzyme active site (Hof
et al., 1998). Binding of N-SH2 domain to its phosphorylated ligand induces a conformational
change that prevents PTP domain binding at a second site (Lee et al., 1994; Eck et al.,
1996). The NS-causing PTPN11 mutations cluster in the interacting portions of the N-SH2
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and PTP domains (Tartaglia et al., 2001). Most of the residues mutated in NS are either
directly involved in these interdomain interactions or in close spatial proximity leading to
constitutively active enzyme.
4 Methyltransferase domains
The human family of DNA cytosine 5-methyltransferases (m5C-MTases) consists of five
family members (reviewed in Bestor, 2000). These enzymes catalyse the transfer of a
methyl group from S-adenosyl-L-methione (AdoMet) to the target cytosine in DNA, with the
exception of DNMT2 that is yet to be established as a catalytically active enzyme (Okano et
al., 1998). DNMT1 acts as the classical maintenance methyltransferase being responsible
for preservation of methylation pattern during DNA replication (Bestor et al., 1988), whereas
DNMT3A, DNMT3B and DNMT3L participate in establishment of de novo methylation
patterns during early embryonic development in a sex-specific manner (La Salle et al.,
2004). The effects of DNA methylation are widespread including transcriptional repression
by methylation of promoter regions (Jones, 1996), formation of compact chromatin structures
(Kass et al., 1997), X-chromosome inactivation (Panning and Jaenisch, 1998) and imprinting
control (Li et al., 1993).
4.1 Methyltransferase domain structure
In addition to the crystal structures of bacterial DNA methyltransferases from Haemophilus
haemolyticus (M. HhaI) and Haemophilus aegypitius (M. HaeIII) (Cheng et al., 1993;
Klimasauskas et al., 1994; Reinisch et al., 1995), only the structure of human DNMT2
m5C-Mtase domain has been solved (Dong et al., 2001). At the structural level, the bacterial
and the human m5C-Mtase structures have a common two-domain structure (Figure 6).
The target DNA segment is bound between the two domains on a surface having positive
electrostatic potential.
The experimental structures have revealed high sequence and structural similarity among
the larger subdomains, whereas the similarity decreases in smaller subdomains. The core
of the larger subdomain is composed of a six-stranded β-sheet sandwiched between two
α-helices (C and D) on one side and two on the other (A and G). The αB-helix runs across
the sheet in front of the sandwich. In contrast to larger subunits, all three known protein
structures have different number and organization of secondary structures (Cheng et al.,
1993; Reinisch et al., 1995; Dong et al., 2001). The conformational variety is required for
recognition and binding of the specific target DNA sequences.
4.2 Methyltransferase domain function
The biochemical and structural analyses with M. HhaI have revealed the common
mechanism of cytosine methylation. The interaction between the M. HhaI and DNA is
dynamic. The target cytosine has two conformations; it is either flipped out from the double
helix to the catalytic pocket near the AdoMet binding site or remains in the stacked state
(Klimasauskas et al., 1998). The residues involved in this process are located in the smaller
subdomain forming the target recognition domain (TRD) loop, the only conserved segment
in the smaller subdomains among the M. HhaI, M. HaeIII and DNMT2. The TRD loop runs
parallel with the DNA strand and serves as a scaffold for conformational processing of the
bound substrate (Cheng and Blumenthal, 1996). Binding of the cofactor induces a
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conformational change in active-site loop located in the larger subdomain. The loop folds
on top of the cytosine locking it into the catalytic site. In the M.HhaI-DNA-AdoMet structure,
arginine 165 and glutamate 119 bind to the cytosine allowing the cysteine 81 to attack the
sixth carbon of the cytosine. This results in the addition of a methyl group to the fifth carbon
of the cytosine followed by elimination of the proton from the fifth carbon and release of the
covalent intermediate (reviewed in Kumar et al., 1994).
Interestingly, the m5C-Mtases do not show binding specificity for the flippable base itself
(Klimasauskas and Roberts, 1995; Yang et al., 1995). Instead, a number of specific
interactions occur between the smaller subdomains and the major groove of the DNA. The
residues involved are generally not conserved and the types of contacts differ between the
known structures, with the exception of the threonine 250 of M. HhaI. This residue is
conserved among the m5C-Mtases and the threonine is involved in conformational change
of the target cytosine backbone as the base flipping occurs (Vilkaitis et al., 2000).
4.3  Diseases related to methyltransferase domain
Mutations in the gene encoding for a DNMT3B lead to a rare autosomal recessive
immunodeficiency, centromeric instability and facial anomalies (ICF) syndrome (OMIM,
242860, Wijmenga et al., 1998. The chromosomes 1, 9 and or 16 are instable in all known
ICF patients (Jeanpierre et al., 1993). These DNA regions contain classical satellites II and
III, which are the major components of constitutive heterochromatin and are normally heavily
methylated (Schuffenhauer et al., 1995; Miniou et al., 1997). In addition to the ICF syndrome,
the expression levels of DNMT3B and its splice variants also play a role in different forms
of cancer (Robertson et al., 1999; Kanai et al., 2001).
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Figure 6. A ribbon model of the methyltransferase domain of Haemophilus haemolyticus (PDB code 6MHT)
showing the secondary structures as in Figure 4. The structure has a typical two subdomain structure. The
target DNA segment binds between the subdomains on a large positively charged surface. The larger subdomain
contains conserved binding sites for the target cytosine and cofactor, S-adenosyl-L-methione, whereas the
smaller subdomain consists of a target recognition (TRD) loop involved in flipping the cytosine from the double
helical DNA conformation into the catalytic pocket of the protein. The cytosine is locked into catalytic site by
active-site loop. The conformation of the larger subdomain is similar in all known methyltransferase structures,
whereas the smaller subdomains differ in sequence and structure.
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5 Aims of the study
Roughly hundred genes have been shown to underlie in various forms of immunodeficiency.
Over the years, we have collated more than 2700 mutations together with patient data into
locus-specific mutation databases. The purpose of the present study was therefore:
• to collate pathogenic mutations into locus-specific databases and to create methods
for maintenance and analysis of the databases.
• to study if the nucleotides surrounding mutation site affect the frequency of mutation.
• to find a computationally suitable way that could be applied for predicting the effect
of small local perturbations occurring on defective protein structures. The method
was applied on two distinct protein domains, Src homology 2 (SH2) and
methyltransferase domains.
•  to validate bioinformatical results, X-linked agammaglobulinemia-linked mutations
were tested by investigating the properties of cloned and produced recombinant
proteins by using various biochemical methods.
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6 Materials and Methods
Detailed description of materials and methods are found in the original publications.
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7 RESULTS
7.1 Locus-specific mutation databases (II, IV, V, VI)
In the present study, we have collected mutations from five different genes, BTK (II), SH2D1A
(IV) as well as SHP-2, p85α of PIP3K and RASA1 (VI), into locus-specific mutation registries.
All encoded proteins include SH2 domain(s) allowing analyses of mutation consequences
on a distinct protein fold. A generic mutation database, SH2base, was created to link results
from the mutational analyses to the locus-specific mutation databases (VI). Furthermore,
ICF causing mutations were collated into DNMT3Bbase (V). All mutation databases have
been updated regularly, and provide the largest publicly available number of different
mutations identified from 1071 patients. The databases are available at http://bioinf.uta. fi/
base_root/.
The database format used in the locus-specific mutation registries follows the guidelines
first adopted in the BTKbase (Vihinen et al., 1999; Vihinen et al., 2001). Each patient forms
an individual entry with a unique accession number and patient identification number (PIN).
The accession number cannot change in any circumstance. PIN is used for indicating the
type and location of a mutation in a simple way, e.g. the first described mutation of arginine
to glycine at position 302 is R302G(1). Family members carrying an identical mutation are
indicated with alphabets following the PIN, e.g. R302G(1a) and R302G(1b). The mutation
consequences are depicted at the corresponding reference sequences by analysing the
effects of the mutation at the genomic DNA through mRNA to protein level. In addition to
mutations, registries contain information about symptoms, age at diagnosis and various
parameters from the patients. Data security protects the patient’s identity, which is not
coded into the registry and not even known by the coordinators of databases. The database
format is understandable without a computer program, but allows development of specific
programs for maintenance and analyses. All databases are currently distributed as flatfiles.
The data in locus-specific registries was used to analyse the different mutation types (II, IV,
V, VI). Majority of intron, deletion and insertion mutations in the databases lead to an
introduction of a termination codon. Furthermore, intron mutations were found to affect
mainly the classical splice sites causing aberrant splice-variants. Generally, insertions and
deletions (indels) are only 1-5 bp of length. Direct repeats were found to appear in the
immediate vicinity of all indels suggesting that these mutations have arisen through DNA
slippage method. Nonsense mutations are located predominantly in the first and third codon
positions with transitions and transversions occuring equally. The majority of missense
mutations (85%) appear in the first two positions within the codon as would be expected.
These two positions primarily determine the coded amino acid. Transitions (56%) dominate
over transversions (42%), although the rate is typically higher for disease-causing mutations
(Stenson et al., 2003).
The CpG dinucleotides form the single most mutated site among the analysed patients (II,
IV, VI). The SH2 domains consist of 69 CpG spots comprising roughly 5% of the coding
regions, with the exception of N-terminal SH2 domain of Zap-70 (21%). Although mutations
were found in only eight sites, deamination of CG to TG or CA constitutes 23 % of all single
base substitutions affecting the SH2 domains. The vast majority of the CpG mutations
affect arginines required for phosphotyrosine binding. A high number of patients result
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from a common DNA mutation mechanism causing a severe enough phenotype to be
clinically observed.
The early version of BTKbase was maintained manually (II). Mutations were collated from
the literature or sent to the BTKbase study group via email in various formats. Partly to
assist and standardize database maintenance, the MUTbase program package was created
(Riikonen and Vihinen, 1999). At the present, the disease-causing mutations are usually
submitted to the particular database coordinators by physicians or directly by the laboratories
performing gene tests using a registry-specific form available in the Internet. The submission
program verifies that the mutation is correctly located at the genomic reference sequence
and determines the consequences at the RNA and protein levels automatically. The mutation
is then emailed to the study group in a complete database format for confirmation. Therefore,
mutations are never included into databases without human verification.
In addition, separate programs were created for SH2base to connect the mutation analyses
and locus-specific mutation databases including patient and mutation data (VI). The
programs separate only SH2 domain affecting mutations from the locus-specific mutation
registries and automatically update tables describing the number of unique mutations and
total number of analysed patients in each SH2 domain. It will also be possible to search
mutations affecting certain positions among the SH2 domains, or to link all mutations causing
particular phenotype to a certain gene or position in the gene. In the near future, the results
of mutation analyses in SH2 domains (VI) will be connected to MultiDisp program (http://
bioinf.uta.fi/cgi-bin/MultiDisp.cgi), allowing e.g. further studies of residue types at particular
position and grouping of proteins based on position specific amino acid frequency.
7.2 Analyses of pathogenic mutations in the DNMT3B (V)
The human DNMT3B belongs to the family of DNA cytosine-5-methyltransferases (m5C-
Mtases) (reviewed in Bestor, 2000). These enzymes catalyse the transfer of a methyl group
from S-adenosyl-L-methinine to the C5 position of cytosine. The effects of DNA methylation
are widespread including e.g. transcriptional repression by methylation of promoter regions
and X-chromosome inactivation (Panning and Jaenisch, 1998). Mutations in the gene
encoding for a DNMT3B, lead to an autosomal recessive Immunodeficiency, Centromeric
instability and Facial anomalies (ICF). The project aim was three-fold: to collate all ICF-
causing mutations into a database (DNMT3Bbase), to analyse the structure-function
consequences of the mutations on the modelled domain structure and to develop a
systematic method for detecting disruptive mutations at the structural level.
The sequence similarity between the DNMT3B and the known methyltransferase enzymes
suggests a similar two-subdomain fold for the DNMT3B as seen in the experimentally
resolved methyltransferase domains. However, this does not unambiguously prove that
the DNMT3B adopts a typical methyltransferase structure. Based on the hypothesis, the
DNMT3B methyltransferase domain was modelled by using Haemophilus haemolyticus
protein structure (PDB code 6MHT) as a template. The structure has been solved with X-
ray crystallography at 2.05 Å resolution (Kumar et al., 1997). As a result of low sequence
similarity between the DNMT3B and template in the region corresponding to smaller
subdomain (amino acids 740-800 and 174-274, respectively), only the larger subdomain
was modeled. The target recognition domain (TRD) –loop was created to illustrate the
single ICF-causing mutation identified in the smaller domain.
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In all known methyltransferase domain structures, the DNA is bound to a large positively
charged surface between the larger and smaller subdomains (Cheng et al., 1993; Reinisch
et al., 1995; Dong et al., 2001). The cytosine is flipped from the target DNA sequence to the
catalytic pocket on the surface of the larger subdomain. The methyl group is transferred to
the cytosine from the cofactor, bound to another binding site next to the cytosine pocket.
The catalytically important residues are located in the larger subunit, whereas all residues
required for recognition of the target DNA sequence and for the flipping of the cytosine
from the double helical DNA structure into the catalytic pocket are situated in the smaller
subdomain. The DNMT3B model has a large positive surface corresponding to the DNA-
binding surface of the larger subunit in the template. The majority of the catalytically important
residues or amino acids required for binding of the cofactor are conserved (Figure 2, V).
Although it was not possible to model the smaller subdomain, the sequence similarity in
TRD loop region between the DNMT3B and the known methyltransferases suggests a
common flip mechanism also for the DNMT3B methyltransferase domain.
Based on the analyses, the disease-causing mutations were found to disrupt the local
structure or remove hydrophobic interface between the domain and the cofactor. Two
mutations, G663S and L664T, affect the flexibility and packing of the active-site loop that
folds on top of the cytosine burying it to the catalytic pocket. Three ICF-causing mutations,
H814R, D817G and V818M appear on the border of a large positively charged surface
next to the DNA and cofactor binding areas. Based on the modelled structure, these
mutations seem not to cause structural alterations and most likely affect either solubility or
an unknown intra/inter molecular binding site. Furthermore, charged residues without a
direct interaction with ligand have been shown to be important for neutralization of residues
in the ligand binding site or making long-range electrostatic interactions with the ligand
(Bradshaw et al., 2000; Sheinerman et al., 2003). To reveal the role of these three residues
in DNMT3B function or stability clearly requires biochemical analyses. The region preceding
the β6 strand in the larger subunit of the DNMT3B model illustrates another example of the
limitations in comparative modelling. The secondary structure predictions indicate only
short β5 strand in DNMT3B, and the program detected no α-helical sequence following the
β5 strand. Furthermore, this region faces the smaller subdomain in all known
methyltransferase structures. Therefore, the model was not used to analyse the effects of
the V726G mutation situated in the loop between β5 and β6 strands.
7.3 Nucleotide neighbourhood in CpG mutations (I)
Majority of methylated cytosines appear in CpG dinucleotides in the human genome. The
CpG dinucleotides are also a known hotspot in many diverse diseases as a result of
spontaneous deamination of 5-methylcytosine to thymine. To examine the effect of nucleotide
neighbourhood surrounding the CpG dinucleotides, mutations affecting CpG sites in five
different diseases were analysed. The genes encode for Bruton tyrosine kinase, factor
VIII, tumour suppressor p53, phenylalanine hydroxylase and protein C. Only protein C
contains a CpG island at the promoter region of the gene. The CpG dinucleotides are
highly suppressed in all genes and they comprised at least a third of disease-causing
missense and nonsense mutations.
Excluding mutations affecting protein C, the most frequently mutated tetra- and
heptanucleotides sequences have a common pattern of YYCGRY/R, where Y denotes for
pyrimidine and R purine (I, tables 2 and 3). The vast majority of the mutated CpG sites in
the protein C are located inside the CpG island where cytosines are typically found
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unmethylated (Bird, 1986). These mutated CpG dinucleotides did not share the YCGR
pattern. No sequence preferences were found for CpNpG triplets (N is any nucleotide but
guanine), although CpNpG sites are stably methylated in mammalian cells at low frequency.
7.4 Putative effects of pathogenic mutations in the SH2 domains (III, IV,
VI)
Mutations in the SH2 domains of Bruton tyrosine kinase (BTK), SH2D1A, Ras GTPase
activating protein (RASA1), Zap-70, SHP-2 and the p85α subunit of the PIP3 kinase (PI3-
K) have been shown to cause nine distinct clinical phenotypes (Table 1, VI). Currently, 168
unique molecular events in 325 unrelated patients have been reported (Table 2, VI). To
examine the putative structural and functional consequences, we have analysed the
mutations on corresponding protein structures. By using sequence entropy, disease-causing
mutations were found to affect conserved positions, or to introduce an unnaturally occurring
side chain in the disease position. Moreover, disease-causing mutations affected covariant
positions among the SH2 domains (Figure 3, VI).
The structural information for the SH2D1A and RASA1 defective SH2 domains was not
available. The RASA1 C-terminal SH2 was modelled based on the crystal structure of N-
terminal SH2 domain of SHP-2 (1AYA, 2 Å resolution) (Lee et al., 1994) (VI). The SH2D1A
SH2 domain was modelled based on the crystal structure of Abl SH2 domain (2ABL, 2.5Å)
(Nam et al., 1996) (IV). Both modelled structures showed typical structural features when
evaluated with PROCHECK program (Laskowski et al., 1993), also used to validate
experimental structures.
The model of the SH2D1A differs from the crystal and NMR structures of the SH2D1A in
two locations (Figure 7). As a result of more open BC-loop conformation in the template Abl
SH2 domain, the model of the SH2D1A was interpreted to interact also with an
unphosphorylated tyrosine in the SLAM receptor (IV). However, the SH2D1A crystal structure
revealed an ordered water molecule replacing the interaction between phosphate group
and RβB5. Furthermore, the interactions with the residues preceding the phosphotyrosine
in the ligand provide additional binding energy (Poy et al., 1999; Hwang et al., 2002). The
structural model also has an incorrect EF-loop structure as the loop in the model follows
the Abl SH2 domain conformation. However, the altered loop conformation had no effect
on mutation analyses. The domain model for SH2D1A was originally used to analyse the
structural consequences of the known XLP mutations (IV), whereas the crystal structure
was used for the analyses in (VI).
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Figure 7. The model of the SH2D1A SH2 domain (grey) superimposed with crystal structure (1D1Z, green)
and averaged NMR structure (1KA7, blue). The major differences occur in EF and BC loops. The backbone
RMSD deviation between the NMR and crystal structures is 1.6 Å. SH2D1A model has a RMSD of 3.2 Å with
the NMR structure and 3.5 Å with the crystal structure and a backbone RMSD for the secondary structures 1.4
Å and 1.6Å, respectively.
One third of the pathogenic mutations affecting SH2 domains either introduce a termination
codon or lead to out of frame translation. Should these variants bypass the nonsense-
mediated mRNA decay machinery, the variant proteins are likely to be extremely unstable.
The XLA and XLP patients also have a large number of gross deletions (20%) causing
deletion of the whole gene locus.  Roughly half of the mutations are single point mutations
at the coding region. Of the 79 different missense mutations, 59% are located on β-strands.
The remaining mutations are situated equally in α-helices and loop structures. Based on
our analyses of the SH2 domain structures, the large majority of missense mutations were
found to affect protein stability (59%). Although missense mutations appear to destabilize
the SH2 domain structure, majority of the mutations affecting identical positions in several
SH2 domains are located on the binding surface. These missense mutations affect highly
conserved residues involved in phosphotyrosine binding as well as unconserved positions
related to SH2 domain specificity (Figure 2, VI).
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7.5 Biochemical analyses of XLA-causing mutations in the SH2
domain of BTK (III)
The structure of BTK SH2 domain has not been solved and a structural model based on
Src SH2 domain (Vihinen et al., 1994) was used instead to choose six XLA-causing mutations
for the analyses. The R307G, Y334S, H358F, Y361C and H362Q mutations affect residues
involved in ligand-binding, whereas G302E mutant was predicted to destabilize the protein
(Figure 1A, III). Furthermore, a non-patient mutation of C337S was introduced to prevent
observed in vitro dimerization of native SH2 domains. The cysteine is located close to the
ligand-binding surface, is largely exposed to solvent and was not predicted to interact with
the ligand. The mutations were analysed for their consequences to the protein structure
and function by using circular dichroism (CD) spectroscopy, and for their ability bind to
phosphotyrosine. The expression of mutated proteins in vitro was studied by creating several
constructs for the analyses. Three of the mutants (R307G, Y334S and G302E) were also
introduced into full-length BTK protein and transiently expressed in COS-7 cells to analyse
the differences in stability between isolated SH2 domain mutants and BTK in vivo.
Circular dichroism spectrum of the wild type BTK SH2 domain showed a typical pattern of
α+β protein. The native SH2 and R307G mutated proteins have identical spectra with broad
minimum in the range of 212-220 nm as a result of overlapping α-helix and β-sheet bands.
The C337S and Y361C CD spectra are highly similar to the spectrum of native BTK SH2
domain, whereas the other mutants studied differed clearly from the native SH2 (Figure 2,
III). The spectra of G302E, Y334S and H362Q have only one minimum at 207 nm and the
spectrum of L358F has two minima at 207 and 214 nm. Although the expression levels of
mutated proteins were increased in lower temperatures, proteins with XLA mutation in
isolated SH2 domains shared reduced solubility and binding of phosphotyrosine (Tables 1
and 2, III). However, the expression levels of full-length mutated BTK proteins were nearly
identical to the wild type and the proteins were not prone to aggregation during analyses.
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8 DISCUSSION
8.1 Creation and analyses of locus-specific mutation databases
In 1952, Dr. Bruton reported the first immunodeficiency in an eight-year-old boy suffering
from agammaglobulinemia (Bruton, 1952). Almost forty years later, the gene affected in
XLA was identified from the X-chromosome, and found to encode a novel cytoplasmic
tyrosine kinase (BTK) (Tsukada et al., 1993; Vetrie et al., 1993). Today, more than 100
different genes have been linked to immunodeficiences, and roughly 1500 genes with other
syndromes. In the present study, mutations from six different genes, BTK, SH2D1A, SHP-
2, p85α of PIP3K, RASA1, and DNMT3B were collated into locus-specific mutation registries
(II, IV, V, VI). In addition, a generic mutation database, SH2base, was created (VI). The
databases were used to analyse the mutation types and mechanisms, especially deamination
of cytosines in CG dinucleotides (I).
The analyses of mutation types in the locus-specific registries show similar distribution as
has been shown for many inherited human diseases (Stenson et al., 2003) (II, IV, V, VI).
The transitions occur more frequently than tranversions, although the rate is not as high as
reported in the HGMD. Furthermore, missense mutations account for roughly half of all
pathogenic mutations in the analysed databases. The insertions or deletions are typically
of 1-5 bp of length with direct repeats at the vicinity favouring the DNA slippage model.
Although the CG dinucleotides were suppressed in almost all analysed genes, point
mutations at the CG dinucleotides comprised 23% of all point mutations (II, IV, VI). Further
analyses of CpG sites in five different pathogenic mutation databases affecting not only
SH2 domains clearly showed that the 5-methylcytosine is more prone to mutate when it
occurs in a specific nucleotide environment (I). In four of the analysed diseases, the most
frequently mutated CpG dinucleotide was preceded by a pyrimidine and followed by a
purine. The environment also differs for CpG dinucleotides located inside a CpG island,
where cytosines are predominantly unmethylated. Krawczak and Cooper have also found
the same nucleotide environment surrounding the CpG site in their analyses for a larger
dataset (Krawczak et al., 1998).
8.2 Mutations affecting SH2 domains
8.2.1 Biochemical analysis of six XLA-causing mutations
The structure of BTK SH2 domain has been modeled based on the Src SH2 domain. The
pairwise sequence identity between BTK SH2 domain and Src SH2 domain is 30%, and
the residues involved in ligand-binding are highly conserved in both domains. Furthermore,
BTK SH2 domain has been shown to interact with the same high affinity peptide pYEEI in
vitro that was complexed with the Src SH2 domain in template structure (Waksman et al.,
1992; Tzeng et al., 2000).
The effect for function of six XLA-causing mutations in the SH2 domain BTK was studied
(III). Five of these mutations (R307G, Y334S, L358F, Y361C and H362Q) were predicted to
affect the ligand binding based on a structural model of the domain. One mutation, G302E,
is located at the AB loop connecting αA-helix to βB-strand. This position is highly conserved
among the SH2 domain and mutation of glycine to glutamate was predicted to disrupt the
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protein structure enabling us to clearly discriminate between functional and structural
mutations. A non-patient mutation, C337S, was originally made to prevent dimerization of
native SH2 domains during purification of this construct for structural studies. The cysteine
is solvent exposed and not involved in ligand binding based on the SH2 domain model.
All XLA-causing mutations were found to reduce solubility and pY binding ability in vitro,
whereas XLA-causing mutations introduced to full-length BTK were shown to share almost
identical in vivo stability and expression levels in COS-7 cells (III). The in vitro stability of
BTK determined by equilibrium denaturation is only 2.9 kcal/mol (Tzeng et al., 2000). The
results indicate that the isolated BTK SH2 domain is only marginally stable, and is therefore
intolerable to even slightly destabilizing mutations.
Changes in CD spectra were used to predict structural and functional consequences of
each mutation (III). The R307G, C337S and Y362C mutated proteins had similar CD spectra
with the native BTK SH2 domain. The R307G mutation corresponds to the invariant RβB5
recognizing phosphotyrosine from the ligand. The R307G mutation does not alter the domain
structure and causes XLA by disrupting the interaction between BTK and BLNK proteins.
In Src SH2 domain structure, the tyrosine corresponding to Y361 of BTK is solvent accessible
and the hydroxyl group extends to the pY+3 binding pocket making a hydrogen bond to the
isoleucine at the pY+3 position of ligand. Based on the BTK SH2 model and biochemical
data of the mutated protein, Y361C mutation causes a mild case of XLA by destabilizing
protein and reducing ligand binding. The spectra of other mutants differed from the wild
type indicating conformational changes of secondary structures in relation to each other.
Furthermore, G302E and L358F mutations have been shown to decrease BTK protein
level in vivo (Saffran et al., 1994; Futatani et al., 1998). Both mutantions introduce a larger
side chain likely to clash with the surrounding residues leading to unpredictable structural
alterations.
8.2.2 Comparison of disease-causing mutations on SH2 domain structures
The analysed missense mutations can be categorized into two groups (III, VI). Mutations
abolishing only SH2 domain function may either affect the enzyme activity as in the case of
PTPN11, or lead to improperly located active enzyme in the cells. The mutations predicted
to be functional deleted crucial hydrogen bonds or lead to loss of hydrophobic interactions
between the SH2 domain and ligand or between the N-terminal SH2 domain of SHP-2 and
the phosphatase domain (VI). As an example, two identical positions were affected in BTK
and SH2D1A SH2 domains leading to XLA and XLP, respectively. The R32T (corresponding
to RβB5) mutation in SH2D1A was predicted to cause XLP by removing the crucial interaction
between the domain and phosphotyrosine (IV, VI). An identical mutation (R307T) has also
been indentified from the BTK SH2 domain. The R307G mutation shared similar CD
spectrum with the wild type BTK SH2 domain but the mutated SH2 domain was unable to
bind phosphotyrosine (III). Furthermore, the R307G mutation was not found to influence
the stability in vivo (Vorechovský et al., 1997).
Mutations affecting the thermodynamic stability or kinetic pathway of folding often lead to
aggregation, as the mutated form either possesses aggregation prone motif on the surface
of the protein or the mutated protein is not able to fold fast enough. A large number of
pathogenic mutations in SH2 domains are not involved in ligand binding. These mutations
were found to influence conserved positions either in the central β-sheet or in the loops
mainly connecting αA helix and βB strand or between αB helix and βG strand (VI). As an
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example, the G302E and G302R mutations in BTK and the corresponding mutation G27F
in SH2D1A affect strictly conserved position in the loop αA helix to βB strand (III, IV). The
glycine is important for the tight turn and correct positioning of the following βB-strand
required for the phosphotyrosine binding. Mutations at this position were predicted to lead
to over-packing and most likely to disrupt the protein structure (VI). In agreement with the
predictions, the CD spectrum of the BTK G302E mutant differed from the wild type and had
a decreased stability in vitro (III). Furthermore, the G302E mutation has also been shown
to decrease the amount of BTK protein in vivo (Futatani et al., 1998).
8.3 Disease-causing mutations affecting methyltransferase domain
of DNMT3B
The sequence analyses and model of the methyltransferase domain of DNMT3B were
used to predict the putative consequences of ICF-causing mutations, possible role of the
different splice variants and specific target DNA sequence for methylation (V). As a result
of low structural homology and sequence identity, only the larger subunit of the
methyltransferase domain could be modeled. Luckily, the majority of the pathogenic point
mutations are located in the larger subunit affecting mainly DNA, cytosine or cofactor binding.
The amino acids in the cofactor and target cytosine binding sites as well as the electrostatic
properties of the binding pockets are conserved.
Based on the sequence similarity, the arginine 764 (R764) of DNMT3B corresponds to
R240 and R227 of the two bacterial methyltransferases, Haemophilus haemolyticus and
Haemophilus aegyptius, respectively. Structural and functional analyses have revealed that
the arginine is involved in recognition of guanine 5’ to the flipped cytosine (Reinisch et al.,
1995; Kumar et al., 1997). The DNMT3B is, therefore, likely to methylate cytosines in the
GCGX sequence context that differs from the environment found for the CpG mutation
hotspots in patients.
Five different DNMT3B splice variants have been described with a tissue-specific expression
behavior. Several of these forms are upregulated in tumours. Of these isoforms, DNMT3B3
has been shown to have important role in vivo (Robertson et al., 1999). The variant protein
contains a 64 residues deletion in the methyltransferase domain excluding specifically the
smaller subdomain. The deletion could represent a natural method to abolish
methyltransferase activity allowing other functions of the protein to predominate.
The DNMT3B project also acted as a pilot project for analyzing a small number of pathogenic
mutations on the corresponding modeled structure before applying the method to a larger
data set affecting SH2 domains (VI). The method and possible future improvements are
discussed in the next chapter.
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CONCLUDING REMARKS
A number of locus-specific mutation databases together with a generic database for the
Src homology 2 (SH2) domains were created, maintained and analysed during the present
study. The results support previously published experimental analyses of the endogenous
mutation mechanisms underlying in pathogenic sequence variations. Interestingly, our results
indicate a role for the flanking nucleotides in the pathogenic CpG hotspots, an observation
that has subsequently been verified by others (Krawczak et al., 1998). The observed CpG
dinucleotides in disease-causing mutations also differ from the predicted target sequence
for the human de novo DNA methyltransferase, DNMT3B. Clearly more analyses are
required to fully understand the role of neighboring nucleotides in mutation mechanisms,
and, especially how nucleotides surrounding CpG sites affect the methylation process,
repair pathway and mutability of the specific CpG spot. In the future, transfer of our locus-
specific mutation databases into a real database format would allow linking of mutation
data with several reference sequence coordinations permitting e.g. comparison of disease
data with normal sequence variations in dbSNP or HGVbase. A large number of sequence
variations together with the published Human Genome sequence would also allow analyses
of nucleotide neighborhood surrounding pathogenic and non-pathogenic sequence
variations.
Missense mutations form the most common mutation type known to cause human genetic
diseases. In the present study, a number of structure related rules for assigning the
consequences of a particular mutation on structural level were introduced. The putative
consequences on corresponding protein structures were predicted for a large number of
different missense mutations in seven different SH2 domains and in the methyltransferase
domain of DNMT3B. As bioinformatical tools are heavily dependent of the biochemical and
biophysical results, the effects of six disease-causing mutations on BTK SH2 domain were
analysed. The developed method predicted correctly XLA mutations for the full length BTK
protein, but failed with some of the functional XLP mutations. Based on the biochemical
analyses, transiently expressed full-length BTK protein with a XLA causing mutation behaves
differently than the seperate BTK SH2 domain carrying identical mutation in vitro. The BTK
SH2 domain alone has been shown to be only marginally stable, and is therefore more
prone to mutations. Similarly, the SH2D1A is comprised of only a SH2 domain followed by
a short C-terminal tail and appears to be intrinsically unstable for mutations. Hence, the
effects of disease-causing mutations on several SH2 domains have to be analysed in
detail to fully understand how the mutation affects the stability of the defective protein
domain in vitro and in vivo. A set of stable model proteins could be used for mutational
analyses in case the disease related SH2 domains are intolerable for mutations. This method,
however, excludes analyses of functional mutations.
It should be possible to automate the current calculations for hundreds of primary
immunodeficiency causing mutations provided that structural information is available or
structural homology exists. Together with sequence-based analyses developed in our
laboratory, these two methods standardize the structure-function analyses of pathogenic
mutations leading to an increase of data quantity and quality in locus-specific mutation
databases. In the future, the next steps for improving the methods involve simulating the
dynamic effects of the protein structures. It would be interesting to use molecular dynamic
simulation techniques with implicit water models to obtain an ensemble of mutated protein
structures for further analyses (reviewed in Lazaridis and Karplus, 2000). It may also be
possible to analyse the effects of disease-causing mutations to the ligand binding by using
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methods such as molecular mechanics Poisson-Bolzmann surface area simulations (e.g.
Huo et al., 2002). Again, the defective SH2 domains provide an excellent model for studying
mutations involved in ligand-binding as number of disease-causing mutations in several
different SH2 domains affect identical positions.
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